Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SPI1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SPI1 Recombinant Protein (WT & DNA-Binding Domain mutants) High purity (>95%), Endotoxin Controlled, Sequence Verified. |
View SPI1 Products |
| Gene Delivery | SPI1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View SPI1 Products |
| Benchmark Ab | Anti-SPI1 Recombinant Antibody Sequence-verified positive control for ChIP, Western Blot, and Flow Cytometry. |
View SPI1 Products |
| Validator | SPI1 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View SPI1 Products |
| Related Target A | CSF1R Downstream receptor heavily regulated by SPI1; critical pathway node in microglial activation and AML. |
View CSF1R Products |
| Related Target B | TREM2 Microglial receptor transcriptionally regulated by SPI1; major genetic risk factor in Alzheimer's Disease. |
View TREM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ETS Family Off-Target Screening | Homolog panel proteins (SPIB, SPIC) strictly verified by mass spectrometry for cross-reactivity profiling. |
| DNA-Binding Inhibition Assays | Truncated SPI1 DNA-binding domain (ETS domain) with high purity (>95%) and verified sequence integrity. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies included for assay standardization. |
| False Positives in Knockdown | Sequence-verified siRNA pools included for highly specific target validation. |
Live SPI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SPI1 (also known as PU.1) therapeutics is intensifying, with major players shifting focus from traditional systemic modulation to targeted small-molecule inhibitors and RNA-based therapies. As first-generation transcription factor modulators reach preclinical and early clinical milestones, the next wave of R&D is targeting cell-type-specific delivery (e.g., microglial targeting in neurodegeneration and leukemia stem cell targeting in AML).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (DB family) | Academic/Biotech Consortia | Acute Myeloid Leukemia (AML) | Biophysical interaction assays (Need high-purity WT/mutant SPI1 proteins) |
| Antisense Oligonucleotides (ASO) | Neuro-immunology Pioneers | Alzheimer's Disease (AD) | Target knockdown validation (Need Lentivirus for stable microglia lines) |
| PROTACs / Degraders | Targeted Protein Degradation Firms | Hematological Malignancies | Ternary complex verification (Need sequence-verified SPI1 and E3 ligase complexes) |